0001209191-23-006990.txt : 20230203
0001209191-23-006990.hdr.sgml : 20230203
20230203170029
ACCESSION NUMBER: 0001209191-23-006990
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220118
FILED AS OF DATE: 20230203
DATE AS OF CHANGE: 20230203
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Leen Ann M.
CENTRAL INDEX KEY: 0001763026
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39409
FILM NUMBER: 23586982
MAIL ADDRESS:
STREET 1: 5 WEST FORSYTH STREET
STREET 2: SUITE 200
CITY: JACKSONVILLE
STATE: FL
ZIP: 32202
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Allovir, Inc.
CENTRAL INDEX KEY: 0001754068
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 831971007
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1100 WINTER STREET
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: (617) 433-2605
MAIL ADDRESS:
STREET 1: 1100 WINTER STREET
CITY: WALTHAM
STATE: MA
ZIP: 02451
FORMER COMPANY:
FORMER CONFORMED NAME: ViraCyte, Inc.
DATE OF NAME CHANGE: 20180924
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-01-18
0
0001754068
Allovir, Inc.
ALVR
0001763026
Leen Ann M.
C/O ALLOVIR, INC.
1100 WINTER STREET
WALTHAM
MA
02451
0
1
0
0
Chief Scientific Officer
Common Stock
2022-01-18
4
A
0
23256
0.00
A
51256
D
Common Stock
2022-07-01
4
A
0
14000
0.00
A
65256
D
Common Stock
2023-02-02
4
A
0
43750
0.00
A
124006
D
Common Stock
2288154
I
See footnote
Stock Option (Right to Buy)
9.15
2022-01-18
4
A
0
56744
0.00
A
2032-01-18
Common Stock
56744
366344
D
Stock Option (Right to Buy)
4.13
2022-07-01
4
A
0
26000
0.00
A
2032-07-01
Common Stock
26000
392344
D
Stock Option (Right to Buy)
6.65
2023-02-02
4
A
0
81250
0.00
A
2033-02-02
Common Stock
81250
473594
D
The shares reported in this transaction represent restricted stock units ("RSUs") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on January 18, 2023, with the remainder vesting in twelve equal quarterly installments thereafter.
The shares reported in this transaction represent restricted stock units ("RSUs") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on July 1, 2023, with the remainder vesting in twelve equal quarterly installments thereafter.
The shares reported in this transaction represent restricted stock units ("RSUs") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on February 2, 2024, with the remainder vesting in twelve equal quarterly installments thereafter.
Shares held by the Ann M. Leen Management Trust, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
25% of this option shall vest and become exercisable on January 18, 2023, with the remainder vesting in twelve equal quarterly installments thereafter.
25% of this option shall vest and become exercisable on July 1, 2023, with the remainder vesting in twelve equal quarterly installments thereafter.
25% of this option shall vest and become exercisable on February 2, 2024, with the remainder vesting in twelve equal quarterly installments thereafter.
/s/ Brett Hagen, as Attorney-in-Fact
2023-02-03